Our group previously showed that the administration of miR-146a reduced the main pathological processes of AD, including glial activation and neuroinflammation, in APP/PS1 transgenic mice, highlighting its potential as a therapeutic target for AD 18. Here, PSEN1 is linked to Alzheimer disease.